At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Glatiramer Acetatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
In Brief
A Phase 2 clinical trial evaluating Glatiramer Acetate for Rett Syndrome. Completed, enrolled 10 participants across 1 site.
Detailed Summary
A phase 2 open label trial to test a potential drug treatment for Rett syndrome, the leading known genetic cause of severe neurological impairment in girls. The drug, Copaxone (generic name - Glatiramer acetate) is medication FDA approved for the treatment of multiple sclerosis. Copaxone's high safety profile has been documented in large cohorts of patients for more than 12 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRett Syndrome
CountriesUnited States
CollaboratorsRett Syndrome Research Trust
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartAug 2013
First PostedJun 2014
Primary CompletionAug 2014
Study CompletionJan 2016
TodayJul 2026
First PostedJun 3, 2014
Enrollment StartAug 1, 2013
Primary CompletionAug 1, 2014
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 12.1 years ago
Interventions
Glatiramer Acetatedrug